John Altin, Ph.D.

Translational Genomics Research Institute

About John Altin, Ph.D.

Dr. Altin began his research career in the immunogenomics lab of Chris Goodnow at the Australian National University. There, he used genome-wide mutagenesis to elucidate several novel molecular and cellular pathways that regulate the helper T cell response, and was recognized as the most outstanding thesis for that year. After his PhD, John joined Prognosys Biosciences, a start-up biotech company founded by Mark Chee (co-founder of Illumina Inc) to develop immunological applications for novel, highly-multiplexed proteomics and genomics assays. There, he led an interdisciplinary team to develop a platform enabling comprehensive analysis of peptide binding to immunological ligands, resulting in a number of issued patents. In 2017, John joined the faculty of the Translational Genomics Research Institute where he has since developed a research program at the intersection of immunology, biotechnology and pathogen genomics. His research brings advances in genomic technology to the study of adaptive immune responses, ultimately in search of improved preventative, diagnostic, and treatment strategies for infectious diseases, particularly those of global relevance.